Effect of Growth Hormone Treatment with Noonan Syndrome: Experience from Kabi International Growth Study (KIGS/ICGS)

Autor:	Patrick Wilton, null Barto Otten on behalf of the International Board
Rok vydání:	1995
Předmět:	Pediatrics medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Kabi Pharmacia medicine.disease Growth hormone Adult height Growth hormone treatment Endocrinology Pediatrics Perinatology and Child Health medicine Noonan syndrome business
Zdroj:	Clinical Pediatric Endocrinology. 4:61-65
ISSN:	1347-7358 0918-5739
DOI:	10.1297/cpe.4.supple6_61
Popis:	55 children, 34 males, 21 females, with Noonan syndrome (NS) included in the Kabi Pharmacia International Growth Study were treated with growth hormone (GH) in a median dose of 0.6 IU/kg/week. Median age at start of treatment was 10.6 years and median height standard deviation score (SDS) was-3.1. Pretreatment height velocity was 4.3 cm/year and during the first, second and third years it increased to 7.0, 6.0 and 4.8 cm/year respectively. Projected adult height with Noonan specific standard increased from -0.4 SDS to 0.3 SDS at the end of three years' treatment. No adverse reactions were reported.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c8dfc86cd269c111f7827bf29b97be6a https://doi.org/10.1297/cpe.4.supple6_61 Zobrazit plný text záznamu